Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Genzyme And Advinus Target Malaria Drugs
September 1, 2008
| A version of this story appeared in
Volume 86, Issue 35
Genzyme and the Medicines for Malaria Venture will work with India's Advinus Therapeutics to develop new drugs to treat malaria. Advinus will contribute its lead and early development capabilities to optimize compounds that target key enzymes in the malaria parasite. The compounds have been identified by a team consisting of researchers from MMV, Genzyme, and the Broad Institute of MIT and Harvard University. MMV has more than 100 industrial, academic, and other partners working on 40 drug R&D projects.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter